Monitor PPCB's post-split trading to see if the stock holds above $1.00 and regains Nasdaq compliance. The Phase 1b study start in Q1 2027 is the next key catalyst.
Price Chart
Executive Summary
Propanc Biopharma announced a 1-for-10 reverse stock split effective October 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from ~10.3M to ~1.0M. The company also reiterated plans to start a Phase 1b FIH study for lead asset PRP in Q1 2027.
Key Facts
- 1-for-10 reverse stock split effective October 26, 2026
- Outstanding shares reduced from ~10,331,116 to ~1,033,112
- Reverse split intended to restore Nasdaq minimum bid price compliance
- Phase 1b FIH study for PRP planned in Q1 2027 in up to 50 advanced cancer patients
Financial Impact
No direct financial impact; reverse split is a mechanical share consolidation with no change to market cap or fundamentals.
Risk Factors
- Post-split price may still fail to maintain $1.00 minimum bid for continued listing
- Phase 1b study may be delayed or produce negative results
- Low liquidity and micro-cap volatility post-split
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386924 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | $2.29 (+717.86%) |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $2.29 (−366.11%) |
Sep 29, 2026 27d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $2.29 (+347.00%) |
Aug 18, 2026 9w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $2.29 (+97.41%) |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $2.29 (+40.49%) |
May 19, 2026 22w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $2.29 (+14.21%) |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $2.29 (+34.71%) |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | $2.29 (+25.31%) |
Apr 21, 2026 27w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | $2.29 (−19.01%) |
Mar 24, 2026 30w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | $2.29 (−17.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers